Momen El Nesr
Addiction Psychiatry · Presque Isle, MENPI 1316981780
Payments from drug & device makers
Across 525 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Lundbeck LLC$968
- plus $3K from 16 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$9,93698%
- Education$2482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,448 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 60 | $1,283 |
| Alkermes, Inc. | 59 | $1,207 |
| Otsuka America Pharmaceutical, Inc. | 65 | $1,127 |
| Vanda Pharmaceuticals Inc. | 62 | $1,027 |
| Lundbeck LLC | 46 | $968 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $847 |
| Sunovion Pharmaceuticals Inc. | 43 | $499 |
| Johnson & Johnson | 13 | $358 |
| E.r. Squibb & Sons, L.L.C. | 8 | $234 |
| Corium, LLC | 8 | $226 |
| Orexo US, Inc. | 13 | $224 |
| Teva Pharmaceuticals USA, Inc. | 9 | $201 |
| Axsome Therapeutics, Inc. | 5 | $135 |
| Indivior Inc. | 6 | $109 |
| Neurocrine Biosciences, Inc. | 4 | $104 |
| Shire North American Group Inc | 3 | $62 |
| Avanir Pharmaceuticals, Inc. | 2 | $44 |
| Vertical Pharmaceuticals, LLC | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Avion Pharmaceuticals | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
How this compares
Too few addiction psychiatry providers in Maineto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 73 | $5,602 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $2,061 |
| Atomoxetine Hcl | 15 | $1,439 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 23 | $813 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 35 | $687 |
| Clonazepam | 75 | $649 |
| Methylphenidate Hcl | 28 | $628 |
| Doxepin Hcl | 26 | $591 |
| Fluvoxamine Maleate | 13 | $362 |
| Quetiapine Fumarate | 25 | $304 |
| Bupropion XlBupropion Hcl | 13 | $249 |
| Benztropine Mesylate | 17 | $239 |
| Gabapentin | 13 | $181 |
| Olanzapine | 26 | $175 |
| Sertraline Hcl | 14 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $109 | $2,06114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in Maineon file to place this against a meaningful peer group, so we don't.
Other addiction psychiatry in Presque Isle
- Jonathan FellersPortland$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.